Rian Hollister: PlasmaFlow As An Option for Continued DVT Prevention
Rian Hollister, Territory Manager at Recon Supply, shared on LinkedIn:
”To all my fellow veterans, ask your VA providers/staff about PlasmaFlow as an option for continued DVT prevention from hospital/medical facility to home.
‘U.S. Centers for Medicare and Medicaid Services (CMS) declared deep vein thrombosis (DVT) a Never Event in 2008, yet it remains the leading cause of preventable death in hospitalized patients each year.’
‘The PlasmaFlow™ Portable Compression Device can reduce DVT risk by providing hospital-quality vascular compression therapy to patients wherever they recover.
DVT risk doesn’t end when a patient is discharged.
With more high-risk surgeries moving from inpatient to outpatient settings, effective compression therapy after discharge is critical.
CHEST guidelines recommend extending thromboprophylaxis in the outpatient period for up to 35 days from the day of surgery for patients undergoing major orthopedic surgery.’
- 60% of HA-VTEs occur after patients have been discharged.
- As many as 70% of HA-VTE cases in patients could be prevented.
“Healthcare-associated venous thromboembolism (HA-VTE) leads to approximately 100,000 premature deaths annually.”
Mean time to presentation for symptomatic DVT:
Total Knee Arthroplasty (TKA) patients = 19.5 days
Total Hip Arthroplasty (THA) patients = 22.5 days
‘The PlasmaFlow™ Portable Compression Device provides continuous DVT prevention for patients returning home to recover.
This portable compression device is comfortable and convenient, ensuring better protection for patients and peace of mind for providers.”’
Stay updated with Hemostasis Today.
-
May 29, 2026, 13:49Tareq Abadl: The Rh Blood Group System – Meet the 5 Antigens That Matter Most
-
May 29, 2026, 13:39Kalyan Roy: Hematopoietic Stem Cell Transplantation in Thalassaemia
-
May 29, 2026, 12:53Wolfgang Miesbach: The Risk of Deskilling in Modern AI Assisted Medicine
-
May 29, 2026, 12:20Pall T. Onundarson: Is Anonymous Peer Review Always Objective
-
May 29, 2026, 11:59Jolene Ng: New Review Explores the Pathophysiology of Pre-Eclampsia
-
May 29, 2026, 11:44Lynne Baird: Why Expanding Bleed Control Kits Across Public Transport Matters
-
May 29, 2026, 11:30Rumbidzai Mushambi: When ‘Just Hormones’ Delays Real Diagnosis
-
May 29, 2026, 09:53Yassin Taher: Recognizing Clonal Eosinophilic Disorders in Pediatric Hypereosinophilic Syndrome
-
May 29, 2026, 09:52Sergio Emanuel Kaiser: Ruvonoflast and a New Anti-Inflammatory Strategy for Residual Cardiovascular Risk